EcoDrugPlus

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSOTSG00005011712
Gene Symbol: CFTR
1 Cross references
210 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSOTSG00005041579
Gene Symbol: LOC112219080
3 Cross references
131 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSOTSG00005026125
Gene Symbol: DNMT1
1 Cross references
204 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSOTSG00005034062
Gene Symbol: DNMT1
1 Cross references
204 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSOTSG00005042272
Gene Symbol: LOC112219831
3 Cross references
201 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSOTSG00005021388
Gene Symbol: LOC112243563
2 Cross references
201 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSOTSG00005026355
Gene Symbol: TOP1
1 Cross references
140 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSOTSG00005043286
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSOTSG00005033681
Gene Symbol: TOP2B
1 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSOTSG00005042624
Gene Symbol: TOP2B
1 Cross references
201 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSOTSG00005020413
Gene Symbol: EML4
1 Cross references
200 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSOTSG00005027887
Gene Symbol: EML4
1 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).